All Stories

  1. Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy
  2. 17th International Conference on Malignant Lymphoma: Key Takeaways
  3. Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents
  4. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
  5. D max : A simple and reliable PET/CT‐derived new biomarker of lymphoma outcome?
  6. Finding a consensus on time‐to‐event endpoints definitions in marginal zone lymphoma: A Delphi method
  7. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study
  8. Marginal-Zone Lymphomas
  9. PET imaging of lymphomas
  10. Radiomics in Malignant Lymphomas
  11. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas
  12. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial
  13. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
  14. Foreword
  15. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
  16. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma
  17. Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas
  18. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
  19. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review
  20. Novel acquisitions on biology and management of transformed follicular lymphoma
  21. Recent advances in understanding the biology of marginal zone lymphoma
  22. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
  23. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias
  24. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
  25. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
  26. Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas
  27. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
  28. Tailoring treatment for MALT lymphoma patients: where do we stand now?
  29. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranoda...
  30. A MALT lymphoma prognostic index
  31. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
  32. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions
  33. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
  34. Unmet needs in the scientific approach to older patients with lymphoma
  35. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study
  36. Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015
  37. Report of the 6th International Workshop on PET in lymphoma
  38. In Reply to Adams and Kwee
  39. Clinical aspects and therapy of gastrointestinal MALT lymphoma
  40. Marginal zone lymphomas: Reconsidering similarities and differences while moving towards personalized treatment
  41. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
  42. Rituximab: 13 open questions after 20years of clinical use
  43. Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma
  44. The landscape of new drugs in lymphoma
  45. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
  46. SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW
  47. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
  48. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  49. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study
  50. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strongin vivoantitumor activity in lymphoma
  51. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
  52. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
  53. Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
  54. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
  55. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
  56. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08
  57. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
  58. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03
  59. Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know?
  60. Reply to G. Keramida et al
  61. Histologic transformation in marginal zone lymphomas
  62. Life expectancy of young adults with follicular lymphoma
  63. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma
  64. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)
  65. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
  66. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models
  67. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)
  68. A Case of Hodgkin Lymphoma in a Patient with a History of Bone Pain and an Initial Diagnosis of Chronic Osteomyelitis
  69. Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al
  70. Primary and secondary bone lymphomas
  71. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
  72. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
  73. Genetic lesions in diffuse large B-cell lymphomas
  74. Management of the Marginal Zone Lymphomas
  75. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
  76. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas
  77. In Reply
  78. Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas
  79. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas
  80. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
  81. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
  82. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
  83. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis
  84. [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study
  85. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
  86. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
  87. Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)
  88. The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)
  89. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)
  90. The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone
  91. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas
  92. Prognostic impact of monocyte count at presentation in mantle cell lymphoma - response to Georgeet al
  93. Discovering Subgroups of Patients from DNA Copy Number Data Using NMF on Compacted Matrices
  94. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  95. Open questions in the management of mantle cell lymphoma
  96. Ten Years of International Primary CNS Lymphoma Collaborative Group Studies
  97. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma
  98. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
  99. Treatment for patients with indolent and mantle cell lymphoma
  100. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)
  101. Toward New Treatments for Mantle-Cell Lymphoma?
  102. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma
  103. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ fromde novodiffuse large B-cell lymphoma
  104. The changing paradigm of chronic lymphocytic leukemia management
  105. Prognostic impact of monocyte count at presentation in mantle cell lymphoma
  106. Genome-wide high resolution DNA profiling of hairy cell leukaemia
  107. Extranodal NK/T-cell lymphoma with leukaemic presentation
  108. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study
  109. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial
  110. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
  111. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
  112. Risk factors of central nervous system relapse in mantle cell lymphoma
  113. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study
  114. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH
  115. Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas
  116. Gains ofCCND3gene in ocular adnexal MALT lymphomas: an integrated analysis
  117. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
  118. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice
  119. 18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
  120. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy
  121. Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial
  122. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
  123. Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells
  124. MYD88 somatic mutations in MALT lymphomas
  125. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer
  126. Incidence, risk factors and outcome of histological transformation in follicular lymphoma
  127. Primary Bone Marrow Lymphoma
  128. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
  129. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate
  130. Absence of NOTCH1 gene mutations in MALT lymphomas
  131. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array
  132. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group
  133. Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma
  134. Diagnosis and treatment of follicular lymphoma
  135. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
  136. First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial
  137. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion
  138. Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype
  139. Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines
  140. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
  141. Genomic profiles of MALT lymphomas: variability across anatomical sites
  142. Integrated profiling of diffuse large B‐cell lymphoma with 7q gain
  143. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas
  144. Epidemiology and management of lymphoma in low‐income countries
  145. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome
  146. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)
  147. Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination
  148. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study
  149. Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and compar...
  150. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
  151. Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
  152. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma
  153. Syk expression patterns differ among B-cell lymphomas
  154. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21
  155. Flows and flaws in primary central nervous system lymphoma
  156. Marginal zone lymphomas
  157. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia
  158. Treatment of gastric marginal zone lymphoma of MALT type
  159. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  160. Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms
  161. IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia
  162. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma
  163. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial
  164. Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features
  165. Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells
  166. Genome wide DNA-profiling of HIV-related B-cell lymphomas
  167. Response: CNS prophylaxis in MCL
  168. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas
  169. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group
  170. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
  171. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
  172. How I treat mantle cell lymphoma
  173. Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome
  174. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
  175. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
  176. Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern Switzerland
  177. The NF- B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
  178. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type
  179. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study
  180. Chlorambucilversusobservation after anti-Helicobactertherapy in gastric MALT lymphomas: results of the international randomised LY03 trial
  181. Extrinsic compression of the pulmonary artery by primary mediastinal large B-cell lymphoma
  182. Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy aloneversuschemotherapy + involved field radiotherapy
  183. First-line treatment of follicular lymphoma–a patient-oriented algorithm
  184. Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?
  185. Marginal Zone Lymphomas
  186. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma
  187. The impact of histopathologic diagnosis on the proper management of testis neoplasms
  188. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion
  189. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma
  190. Primary testicular lymphoma
  191. Challenging issues in the management of extranodal lymphomas
  192. Extranodal Lymphomas
  193. Gastrointestinal tract lymphomas
  194. Who should receive myeloablative therapy for diffuse large B-cell lymphoma?
  195. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS
  196. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
  197. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
  198. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group
  199. Primary testicular lymphoma
  200. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
  201. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review
  202. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment
  203. Primary CNS Lymphomas Prognosis
  204. Marginal-zone lymphoma
  205. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas
  206. Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting
  207. Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases
  208. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
  209. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions
  210. Revised Response Criteria for Malignant Lymphoma
  211. Epidemiology of hematological malignancies
  212. Management of elderly patients with hematological neoplasms
  213. Bendamustine in lymphomas: More to combine?
  214. ConcomitantMYCand microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma
  215. Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type
  216. Low prevalence ofChlamydia psittaciin ocular adnexal lymphomas from Cuban patients
  217. A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals
  218. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?
  219. Chlamydia or Not Chlamydia, That Is the Question: Which Is the Microorganism Associated With MALT Lymphomas of the Ocular Adnexa?
  220. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas
  221. Marginal Zone B-Cell Lymphomas
  222. Delving deeper into MALT lymphoma biology
  223. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
  224. Primary Pulmonary Lymphoma: Current Status
  225. State-of-the-Art Therapeutics: Marginal-Zone Lymphoma
  226. Another Piece of the MALT Lymphomas Jigsaw
  227. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
  228. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
  229. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy
  230. Mantle cell lymphoma
  231. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’1
  232. Follicular Lymphoma International Prognostic Index
  233. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma
  234. ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis
  235. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
  236. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
  237. Molecular basis of mantle cell lymphoma
  238. Pathobiology of Primary Mediastinal B-Cell Lymphoma
  239. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
  240. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma
  241. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
  242. International Collaborative Group Against Primary CNS Lymphomas
  243. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
  244. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
  245. Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients
  246. ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma
  247. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group
  248. Primary Mediastinal B-Cell Lymphoma
  249. Mantle Cell Lymphoma: New Treatments Targeted to the Biology
  250. Treatment of extranodal lymphomas
  251. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies
  252. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial
  253. Relevance of intraocular involvement in the management of primary central nervous system lymphomas
  254. Genetic alterations underlying the pathogenesis of MALT lymphoma
  255. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies
  256. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes
  257. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers
  258. Localized non-Hodgkin's lymphoma of Waldeyer's ring: Clinical features, management, and prognosis of 130 adult patients
  259. Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 66 patients
  260. Analysis ofFas/CD95 gene somatic mutations in ovarian cancer cell lines
  261. BCL10 gene mutations rarely occur in lymphoid malignancies
  262. Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma
  263. Association of gastric and Waldeyer's ring lymphoma: a molecular study
  264. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas
  265. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin
  266. Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAlu— Polymerase Chain Reaction
  267. Prognostic models for diffuse large b-cell lymphoma
  268. Extranodal lymphomas
  269. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma
  270. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study
  271. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites
  272. Microsatellite instability in gastric MALT lymphomas and other associated neoplasms
  273. Molecular Genetics of Extranodal Marginal Zone (MALT-Type) B-Cell Lymphoma
  274. Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma
  275. Primary Mediastinal Large B-Cell Lymphoma: The Need for Prospective Controlled Clinical Trials
  276. Primary Mediastinal Large B-Cell Lymphoma (PMLCL): The Need for Prospective Controlled Clinical Trials
  277. ChlVPP/ABV-VP16 Hybrid Regimen for Advanced Hodgkin's Disease: a Study in 36 Patients
  278. Clonality Assessment in Blood of Patients with Mantle Cell Lymphoma
  279. Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature
  280. Report of the European Task Force on Lymphomas: Workshop on peripheral T-cell lymphomas
  281. Therapeutic use of monoclonal antibodies: A new era?
  282. Distribution of Mobilized Progenitor Cells in the Buffy Coat of the Haemonetics MCS3p Cell Separator: A Study to Optimize the Collection of Progenitors by Leukapheresis
  283. Molecular Analysis of the Progression from Helicobacter pylori –Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach
  284. Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach
  285. Gastric Mucosa-Associated Lymphoid Tissue Lymphomas: More Than a Fascinating Model
  286. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas
  287. Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature
  288. Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma
  289. Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process
  290. Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT Lymphoma
  291. Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas
  292. 6 Gut lymphomas
  293. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphoma
  294. Biology and treatment of MALT lymphoma: The state-of-the-art in 1996
  295. Cell cycle regulation and the function of cancer genes
  296. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma
  297. Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue
  298. Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma
  299. Patterns of survival in mantle cell lymphoma
  300. Book review
  301. Book review
  302. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL)
  303. Treatment and Prognosis of Centrocytic (Mantle Cell) Lymphoma: A Retrospective Analysis of Twenty-six Patients Treated in One Institution
  304. Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis
  305. Book review
  306. Direct sequence analysis of 14q+ and 18q- chromosome junctions at the MBR and MCR revealing clustering within the MBR in follicular lymphoma
  307. Enzymuria in Carboplatin Nephrotoxicity
  308. Polarographic Assay of Submicrogram Quantities of Cis-Dichlorodiamineplatinum (II) in Biological Samples
  309. MALT and other marginal zone lymphomas